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Abstract
Reactive antigenic epitopes on presumed autoantigens of biologic interest have been
examined by many researchers. The central third complementarity-determining region (CDR3)
residues of a human monoclonal anti-proteinase 3 (PR3) antibody contained many negatively
charged aspartic acid residues, perhaps contributing to its reactivity with positively charged
PR3 regions. Examination of four other human monoclonal anti-PR3 antibodies shows a
number of negatively charged residues within their CDR3 regions. Mapping of segments of
linear PR3-epitopes reacting with anti-neutrophil cytoplasmic antibodies (ANCA) demonstrated
a preliminary estimate of structures contributing to antigenic determinants. T-cell epitopes on
PR3 are reported in studies of chronic myeloid leukemia. These T-cell epitopes appear to be
human leukocyte antigen (HLA) A2.1 restricted.
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ANCA = anti-neutrophil cytoplasmic antibodies; CDR3 = third complementarity-determining region; ELISA = enzyme-linked immunosorbent
assay; Fab = antigen-binding fragment; Fc = crystallizable fragment; HLA = human leukocyte antigen; HMC = human mast cell; mAb = mono-
clonal antibody; PMN = polymorphonuclear leukocytes; PR3 = proteinase 3; rPR3 = recombinant proteinase 3; V regions = variable antibody
regions; WG = Wegener’s granulomatosis.
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Introduction
Exactly how polyclonal or even monoclonal human autoanti-
bodies actually bind to their respective antigens on PR3 is
still not completely understood, but because of its strongly
overall positive charge, PR3 should show at least an elec-
trostatic attraction for negatively charged amino acids
within the antibody-combining site. We recently followed
this line of reasoning in attempting to construct a three-
dimensional model of the combining site of a monoclonal
human IgM anti-PR3 antibody (WGH1) using a molecular
modeling technique that made use of knowledge-based
homology modeling to obtain minimum-energy conforma-
tional approximations [1•].
This interesting antibody, which originated from a patient
with Wegener’s granulomatosis (WG) [2], showed the
unique amino acid sequence DFWSGYYRDQYY within
the CDR3 region of the heavy chain. The CDR3 contained
an unusually high number of negatively charged aspartic
acid residues (D), which were postulated to be capable ofArthritis Research    Vol 2 No 4 Peen and Williams
reacting with the positively charged epitopes of PR3.
Moreover, our molecular model indicated that the CDR3
structure of the monoclonal autoantibody WGH1
appeared to be involved in the formation of a loop that lay
on the surface of the first variable region of the heavy
chain and thus was accessible for interaction with pre-
sumably positively charged residues on PR3. Moreover,
the light-chain CDR3 of this antibody showed a glutamic
acid (E) at position 100, towards the end of the light
chain. Glutamic acid is another amino acid with a strong
negative charge, also capable of reacting with positively
charged PR3. For these observations to bear weight, it
was assumed that the CDR3 of WGH1 constituted the
central portion of the antibody-combining site. Recent
observations by Corper and coworkers concerning the
crystal structure of a human IgM rheumatoid factor Fab
binding to its presumed Fc autoantigen, surprisingly indi-
cated a rather novel topology of the autoantibody–antigen
interaction, namely, that although the CDR3 region of the
antibody was engaged, it appeared to be only at the edge
of the complementarity-determining region rather than in
the middle [3]. These latter observations could, of course,
suggest that rheumatoid factors may have primary speci-
ficity for something besides the Fc of IgG, a possibility
that makes some of our previous observations all the more
interesting [4,5].
The report by Corper and coworkers was the first descrip-
tion of the three-dimensional structure of a human autoan-
tibody reacting with its presumed autoantigen. That
landmark observation may imply that rheumatoid factor
reacting with the Fc of IgG represents only part of the
specificity of the antibody-combining site itself. The same
might be said of other autoantibodies, such as human anti-
bodies reacting with PR3 or myeloperoxidase. Since the
beginning of modern clinical immunology around the
middle of the 20th century, many human autoantibodies
have been defined on the basis of the original assay used
to detect them. This is the case with rheumatoid factors or
anti-nuclear antibodies and possibly also with C-ANCA
and anti-PR3 antibodies. It is possible that the methods
used to detect various autoantibodies unduly influence our
final judgement of what the initial antigenic stimulus was
for their generation. Perhaps this misgiving can be laid to
rest once the crystal structure of human anti-PR3 reacting
with PR3 has been defined, if the CDR3 interactions with
the relevant PR3 residues are shown to be of very high
affinity and solidly tight within most of the antibody-com-
bining site surface.
While we were busy sequencing and later modeling the
variable (V) regions of our mAb WGH1, Sibilia and
coworkers in France published the V-region sequences of
five other human monoclonal autoantibodies reacting with
PR3 [6•]. Those workers’ CDR3 heavy-chain sequences
show many similarities to those we found in our WGH1.
Four heavy-chain CDR3 sequence motifs recorded by the
French group are shown in Table 1. It can be seen that
human monoclonal IgM anti-PR3 WG1 showed only a
single negatively charged aspartic acid (D), in the very
center of the CDR3. On the other hand, mAbs WG2 and
WG3 showed multiple negatively charged glutamic acids
(E) or aspartic acids (D) throughout the heavy-chain
CDR3. mAb WG4, however, showed only a single aspar-
tic acid, near the center of the heavy-chain CDR3. The
light-chain CDR3 regions and the adjoining sequences of
several of these monoclonal antibodies are also shown in
Table 1. WG2 showed both aspartic acid and glutamic
acid together in Framework 3 region, just before the light-
chain CDR3, whereas WG3 and WG4 showed an aspar-
tic acid at the end of the JK3 segment. In general, though
the French group’s sequences have not been subjected to
modeling, their results also uphold the notion that nega-
tively charged residues within or near the CDR3 regions
may help determine anti-PR3 specificity. For the negatively
charged residues shown in Table 1 to be important in the
interaction of these regions of the monoclonal anti-PR3
antibodies with antigenic determinants on PR3 (an overall
Table 1
Structural and sequence comparisons of V-region heavy-chain (VH) and light-chain (VL) amino acids in several human monoclonal
IgM anti-PR3 autoantibodies
Designation [Reference] VH CDR3 sequence VL CDR3 sequence
WGH1 [1•] SQMSYYDFWSGYYRDQYY SSYTSSSTEV
WG1 [6•] VAVAGGFDPWGQGTLVT
WG2 [6•]G EIDFWSGYFREGLVGP (EDFATYYC)LQHNSYP
¬ JK3          ®
WG3 [6•] RGIFEGSGYYALDDWGQG QQYYGTPFTFGPGTKVDIKR
¬ JK3       ®
WG4 [6•] SRGTSCYMSCDCWGPRTL QQHYGTPFTFGTKVDIKR
Sequence in parentheses is PR3. Amino acids shown in bold type are very negatively charged.http://arthritis-research.com/content/2/4/255
positively charged molecule), one must assume that the
actual reactive three-dimensional or linear determinants on
PR3 would conversely have to bear strong positive
charges. At present this particular point is not clear, since
an overall scheme defining reactive PR3 conformational
determinants has not been identified.
Studies of recombinant PR3 as an antigen
reactive with various antibodies
Precise designation of reactive linear or three-dimensional
determinants on presumed autoantigens such as PR3 or
myeloperoxidase has often proved a formidable task. With
respect to PR3, the initial report by Bini and coworkers [7•]
indicated that C-ANCA sera from patients with WG
showed little or no binding to recombinant PR3 (rPR3)
expressed as a fusion protein in Escherichia coli. These
workers found that the antigenicity of PR3 was totally
destroyed by exposure to reducing agents or to low pH
(<3.0) and was lost or considerably diminished after boiling
in SDS. They concluded that the reactive sites on PR3 must
be conformational epitopes. Subsequent studies by Witko-
Sarsat et al [8], using a baculovirus/insect cell system, pro-
duced another recombinant PR3 as a glycosylated
intracellular and membrane-associated protein. Rabbit anti-
PR3 IgG recognized both rPR3 and neutrophil-derived
PR3; however, sera from patients with WG reacted only
with neutrophil-derived PR3 and not with the baculovirus
rPR3 preparation. These studies also showed that PR3 anti-
genicity was conserved in 8M urea or 1% SDS, indicating
that the antigenic epitopes were maintained by disulfide
bonds even in denaturing conditions. This particular PR3
preparation did not show serine proteinase activity, and the
authors indicated that absence of serine protease activity
and of C-ANCA reactivity suggested that this rPR3 exhib-
ited aberrant folding. Other studies conducted in this report
also indicated that autoantibody recognition of PR3 epi-
topes appeared to be polysaccharide-independent in poly-
morphonuclear leukocyte (PMN)-derived PR3.
Additional studies of rPR3 were reported by Specks et al
[9•,10]. A stable expression system for conformationally
intact rPR3 used the human mast cell line HMC-1 [9•].
This rPR3 preparation showed serine preotease activity
and reacted with most C-ANCA positive sera from
patients with WG. Of interest in this study was the fact
that two additional proteins of ~47 and 83 kDa were co-
immunoprecipitated by PR3 specific antibodies from
lysates of both HMC-1 as well as U937 cells. Similar find-
ings had previously been reported by Goldschmeding et
al [11] in immunoprecipitates using C-ANCA patient sera
from neutrophil granule extracts. Characterization of these
additional proteins eventually will be of interest. When
Specks and coworkers completed a comparative study of
indirect immunofluorescence and ELISA results using a
large number of C-ANCA-positive sera and other samples
from patients with biopsy-proven WG, they found that
three C-ANCA-negative patients with biopsy-proven WG
showed rPR3-ANCA detectable on HMC-1 PR3 cells.
Other workers have also reported positive indirect antigen
capture ELISA results obtained using the open reading
frame of PR3 without the prepro-peptide and using a
Pichia pastoris expression system [12]. In that study, 60%
of sera from patients with WG bound to recombinant
product. Precise localization of reactive conformations
within recombinant PR3 must now be attempted.
Mapping of antigenic determinants within PR3
In 1994, we attempted to define linear antigenic regions
within the surface-exposed portions of PR3 by using over-
lapping peptides derived from the primary amino acid
sequence [13•]. That study was facilitated by Dennis
Underwood’s creation of a three-dimensional model of PR3
on the basis of the sequence homologies between PR3
and 20 other serine proteases. Eleven surface-exposed
regions composed of 7mers of PR3 linear sequence were
identified, none of which, curiously, showed any primary
sequence homology. Two of these 7mer peptide epitopes
(ATVQLPQ and RVGAHDP) were studied in detail. Inhibi-
tion of dilutions of WG sera C-ANCA staining of PMNs on
slides was demonstrated by preincubation of WG serum
with each peptide. Moreover, IgG F(ab)2 fragments from
rabbit antisera to each of the peptides showed C-ANCA
staining of human neutrophils. In 1996, Fujinaga et al
reported the crystal structure of PR3 and suggested on the
basis of our data on reactive linear epitopes that these
reactive regions might correspond with flexible parts of pro-
forms of the serine protease enzyme [14•]. These workers
suggested that the flexible regions in the pro-enzyme forms
of PR3 might be secreted or otherwise externalized on the
cell surface and thereby trigger the antigenic stimulus in
WG. An illustration of the three-dimensional carbon trace
of PR3 with the linear determinants we suggested as anti-
genic sites reacting with C-ANCA antibodies is illustrated
by the blue outlines in Fig. 1, adapted from Fujinaga’s
report. Clearly, more work is needed to define conforma-
tional antigenic determinants present on PR3.
Additional studies of antigenic epitopes on PR3 were later
reported by Chang et al [15], who used dot blots, ELISA,
and synthesized 10mers of PR3 sequence on pins. These
workers found no peaks of specific ELISA reactivity corre-
sponding to regions of PR3 overlapping linear sequence,
and no difference between sera from patients with WG and
normal controls. Chang et al used an ELISA assay system
very similar to the one we used, but they tested 10mers
instead of 7mers. Their much longer peptides may somehow
have obscured the relevant antigens when they performed
the tests. However, additional epitope mapping studies
recently reported by van der Geld and coworkers [16] again
showed five reactive regions and indicated higher values
with WG sera than those seen with normal controls.T-cell epitopes on PR3
If immune reactivity to antigenic determinants of PR3 is
fundamental to pathogenesis in WG, then one might also
expect that such patients would develop cell-mediated
immune reactivity to T-cell-reactive determinants on PR3.
Several recent observations by Molldrem et al relating to
myelogenous leukemia [17•,18] have indicated that a
9mer peptide of PR3, VLQELNVTV (residues 169–177),
was restricted to HLA-A2.1 and could be used to sensitize
a human leukocyte antigen (HLA)-A2.1 T-cell line specific
for the 9mer PR3 peptide VLQELNVTV. Specific lysis of
the cells carrying PR3 peptide at an effector-cell to target-
cell ratio of 50:1 was recorded. Since PR3 was known to
be present in high concentration in the primary granules of
both acute and chronic myeloid leukemia blasts, this
approach was undertaken as a possible strategy for
therapy of such hematologic malignancies as acute or
chronic myelogenous leukemia recurring after aggressive
chemotherapy. Later work by the same group indicated
that the PR3 peptide VLQELNVTV-specific T-cells
obtained from two HLA-A2.1+ normal individuals showed
specific cytotoxicity for the nonpolymorphic PR3 peptide
and could inhibit chronic myeloid leukemia colony-forming
units [18]. These observations are of great interest: they
suggest why no particular narrow HLA phenotype has
ever been identified in WG, since approximately half of
normal individuals are HLA-A2.1+. If cell-mediated immune
reactivity to antigenic determinants on PR3 required only
the presence of HLA-A2.1, more than half the general
population expressing HLA-A2.1 would be susceptible, so
that clearly other immunogenetic factors must be involved
in the eventual development of WG.
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